Investigational drug · Phase 3
TDV
Also called: TAK-003, Tetravalent Dengue Vaccine, QDENGA
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dengue Fever, Healthy Volunteers.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
26
Any phase or sponsor naming "TDV"
First trial start
2024
Mar 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TDV", any sponsor or status.
- Phase 313
Conditions studied
As listed on its trial records.
- Dengue Fever
- Healthy Volunteers
Largest trials
Live from ClinicalTrials.gov: studies naming "TDV" as an intervention, largest first.
- Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy ChildrenPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02747927 · 20,099 participants · Start Apr 26, 2016 · Primary completion Jul 11, 2018
Drug: Placebo; Tetravalent Dengue Vaccine (TDV) · For: Healthy Volunteers
Sites: Vitória, Brazil; Salvador, Brazil; Campo Grande, Brazil · 28 sites in all
Albert B. Sabin Vaccine InstituteAcademic, hospital or other
NCT03960385 · 1,854 participants · Start Aug 1, 2017 · Primary completion Mar 1, 2020
Drug: CYD-TDV · For: Dengue
Sites: São Paulo, Brazil
- Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy ParticipantsPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02302066 · 1,800 participants · Start Dec 5, 2014 · Primary completion Feb 18, 2019
Drug: Takeda's Tetravalent Dengue Vaccine Candidate (TDV); TDV Placebo · For: Dengue Fever
Sites: Santo Domingo, Dominican Republic; Panama City, Panama; Dasmariñas, Philippines
- Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02193087 · 1,002 participants · Start Aug 6, 2014 · Primary completion May 19, 2015
Drug: TDV Liquid Formulation 1; TDV Liquid Formulation 2 and 2 more · For: Dengue Fever
Sites: Phoenix, Arizona; Anaheim, California; Stockbridge, Georgia · 7 sites in all
- Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for DenguePivotal-lookingCompleted
TakedaTakeda (TAK)
NCT03423173 · 923 participants · Start Feb 12, 2018 · Primary completion Aug 3, 2018
Drug: TAK-003; Placebo · For: Dengue Fever
Sites: Huntsville, Alabama; Anaheim, California; Boise, Idaho · 14 sites in all
- Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus VaccinePivotal-lookingCompleted
TakedaTakeda (TAK)
NCT03525119 · 900 participants · Start May 16, 2018 · Primary completion Oct 3, 2018
Drug: TDV; HAV Vaccine and 2 more · For: Healthy Volunteers
Sites: Edgbaston, United Kingdom; Chorley, United Kingdom; Waterloo, United Kingdom · 10 sites in all
- Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in AdultsPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT03342898 · 900 participants · Start Feb 28, 2018 · Primary completion May 9, 2018
Drug: YF-17D; TDV and 1 more · For: Dengue
Sites: Mobile, Alabama; Pomona, California; Meridian, Idaho · 11 sites in all
- A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)Pivotal-lookingActive, not recruiting
TakedaTakeda (TAK)
NCT06579755 · 800 participants · Start Jan 20, 2026 · Primary completion Apr 14, 2027
Drug: TDV · For: Dengue Fever
Sites: Buenos Aires, Argentina; Salvador, Brazil; São José do Rio Preto, Brazil · 7 sites in all
- Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 YearsPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT04313244 · 614 participants · Start May 15, 2021 · Primary completion Feb 21, 2022
Drug: 9vHPV Vaccine; Dengue Tetravalent Vaccine (TDV) · For: Dengue Fever
Sites: Bangkoknoi, Thailand; Bangkok, Thailand; Pathum Thani, Thailand · 4 sites in all
- A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy AdultsPivotal-lookingActive, not recruiting
TakedaTakeda (TAK)
NCT07047521 · 496 participants · Start Nov 7, 2025 · Primary completion Jun 29, 2026
Drug: Tetravalent Dengue Vaccine (TDV) · For: Dengue Fever
Sites: Blacktown, Australia; Botany, Australia; Kanwal, Australia · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- What Vaccines Teach Us About Dengue Immunity.
Halstead SB · J Infect Dis 2026
- El Niño 2026-2027 and DENV-3 in Latin America: A Narrowing Window for Preparedness.
Khan S, Croda J · J Infect Dis 2026
- Factors associated with TAK-003 dengue vaccine acceptance among Thai adults using the Health Belief Model and Theory of Planned Behavior in a tertiary care hospital.
Thanatepaisansakun T, Homsanit M, Chalermsri C, et al. · Vaccine 2026
- CD8+ T cells and humoral immunity may mitigate the effects of antibody-dependent enhancement: implications for dengue vaccine design.
Drake RS, Ahmed H, Chandele A, et al. · J Virol 2026
- Real-world Evidence on dengue vaccine effectiveness: a systematic review of post-licensure evidence and methodological gaps.
Goraczka S, Ghilardi FR, Launay O, et al. · Int J Infect Dis 2026
- Metabolic Screening and In Silico Investigation of Eucalyptus globulus Essential Oil Bioactives Against DENV-2 Envelope Protein.
Afzal A, Ahmad I, Mahadullah, et al. · ChemistryOpen 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.